What the FDA labels say about taking them together
Digoxin and rabeprazole
Digoxin's FDA label of December 5, 2024 names rabeprazole in its drug interactions section, and rabeprazole's label names digoxin too. The rabeprazole label: “Potential for increased exposure of digoxin.”
Check it at the source: the digoxin FDA label on DailyMed (effective December 5, 2024, Advanz Pharma (US) Corp.); the rabeprazole FDA label on DailyMed (effective January 27, 2026, Waylis Therapeutics LLC).
What does the digoxin label say about rabeprazole?
Digoxin label, drug interactionsRabeprazole; 29%; 19%; Measure serum digoxin concentrations before initiating concomitant drugs. Reduce digoxin concentrations by decreasing the dose by approximately 15-30% or by modifying the dosing frequency and continue monitoring.
Source: FDA drug label (Digoxin, NDA021648), Hikma Pharmaceuticals USA Inc., effective April 10, 2025 (SPL set 1b7e5c6e-e052-41b0-a4ce-05dfe62faaaf), via openFDA
Source: FDA drug label (LANOXIN), Advanz Pharma (US) Corp., effective December 5, 2024 (SPL set d91e3646-4c63-4512-ab22-db39c085c4dc), via openFDA; the full label on DailyMed
What does the rabeprazole label say about digoxin?
Rabeprazole label, drug interactionsClinical Impact: Potential for increased exposure of digoxin. Intervention: Monitor digoxin concentrations. Dose adjustment of digoxin may be needed to maintain therapeutic drug concentrations. See prescribing information for digoxin.
Rabeprazole label, warnings and precautionsFor patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ].
Source: FDA drug label (Aciphex), Waylis Therapeutics LLC, effective January 27, 2026 (SPL set 1eb38279-0237-4967-be7a-c53a826c1138), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Digoxin | Rabeprazole | |
|---|---|---|
| Labeled for | Heart failure, Atrial fibrillation | Acid reflux and ulcers |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $0.133 per tablet 125 mcg tablet | $0.224 per tablet 20 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once